Clinical Trial Update: Clinical Trial of MK0683 in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC (MK0683-058) [Phase 1]

View source ↗

Summary

This Phase 1 trial update reports results for MK0683 in combination with FDA-approved cancer drugs in patients with advanced non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• MK0683 (MK-0683)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-Small Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2011-08-02